Recent News

• 04.09.2025 - Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
• 04.09.2025 - Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
• 04.09.2025 - Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
• 04.01.2025 - Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
• 04.01.2025 - Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
• 04.01.2025 - Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
• 03.10.2025 - Leerink's Global Healthcare Conference 2025
• 03.10.2025 - Leerink's Global Healthcare Conference 2025

Recent Filings

• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - 8-K Current report
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities